Precigen, Inc. (NASDAQ:PGEN), a biotechnology company specializing in gene and cell therapies with a market capitalization of $398.3 million, is on the cusp of a significant transformation as it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback